Antibody concentrations lower in infliximab-treated individuals with IBD receiving single dose of BNT162b2 or ChAdOx1 nCoV-19 vaccine<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, May 18, 2021 (HealthDay News) — Individuals with inflammatory bowel disease who are treated with infliximab rather than vedolizumab have reduced immunogenicity to a single dose of BNT162b2 and ChAdOx1 nCoV-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, according to a study published online April 26 in Gut<\/em>.<\/p>\n Nicholas A. Kennedy, M.B.B.S., from the Royal Devon and Exeter NHS Foundation Trust in the United Kingdom, and colleagues compared antibody responses and seroconversion rates in 865 infliximab-treated patients and a cohort of 428 patients treated with vedolizumab. The primary outcome was anti-SARS-CoV-2 spike antibody concentrations measured three to 10 weeks after vaccination.<\/p>\n The researchers found that compared with patients treated with vedolizumab, patients treated with infliximab had lower geometric mean anti-SARS-CoV-2 antibody concentrations following the BNT162b2 and ChAdOx1 nCoV-19 vaccines. Antibody concentrations were lower in infliximab- versus vedolizumab-treated patients who received the BNT162b2 and ChAdOx1 nCoV-19 vaccines in multivariable models (fold change, 0.29 and 0.39, respectively). Anti-SARS-CoV-2 antibody concentrations were lower in association with age 60 years and older, immunomodulator use, Crohn disease, and smoking, and they were higher in association with non-White ethnicity in both models. Patients with prior SARS-CoV-2 infection had higher seroconversion rates after a single dose of either vaccine and after two doses of the BNT162b2 vaccine.<\/p>\n “Our findings come as countries across Europe are opting to delay the second dose of vaccine,” a coauthor said in a statement. “We recommend prioritizing second doses to patients taking anti-tumor necrosis factor drugs, who will remain at high risk after their first dose.”<\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry, including several companies that provided study funding.<\/p>\n